DESIGNED TO HELP ADDRESS A RANGE OF PATIENT NEEDS
Which of your mild to moderate AD patients might benefit from OPZELURA?


Needs meaningful relief from mild to moderate AD itch: Isabelle, 23
“I really want something that will help stop the itching.”
Patient portrayal.

Her AD story
- Works in a fast-paced environment as a professional chef but is constantly slowed down by chronic itch
- Often feels irritable after nights of scratching, which exacerbates her lesions
Her treatment needs
- Has tried multiple TCSs over the years
- Experiences temporary relief between
flare-ups - Lesions have increased from 5% to 8% BSA
Patient portrayal.
See if your patients are eligible to save on their prescription >
AD=atopic dermatitis; BSA=body surface area; TCS=topical corticosteroid.


Wants a treatment for her mild to moderate AD in sensitive skin areas*: Sarah-Beth, 59
“It's difficult to find relief where I need it.”
Patient portrayal.

Her AD story
- Proud shop owner who has eczema on face and upper chest
- Self-conscious about the ointment she uses, which has a greasy appearance and causes stinging
Her treatment needs
- Dissatisfaction with tacrolimus has left her doubtful of other options
- Needs a targeted therapy that can relieve mild to moderate AD in sensitive skin areas*
*For topical use only. Not for ophthalmic, oral, or intravaginal use.1
RESULTS >
Patient portrayal.
See if your patients are eligible to save on their prescription >
AD=atopic dermatitis.
Reference: 1. Opzelura. Prescribing Information. Incyte Corporation; 2021.


Wants a nonsteroidal option that is appropriate for use on areas affecting her every day*: Faith, 40
“I wish I had a different option to control my AD symptoms.”
Patient portrayal.

Her AD story
- Has suffered from mild to moderate AD for
more than 2 years and is prescribed a TCS - Works as a registered nurse, which requires constant hand and forearm washing that exacerbates her AD
- Worried that her open lesions are unhygienic
Her treatment needs
- Wants to avoid mild atrophic patches in affected areas caused by long-term TCS use
- Needs a nonsteroidal option that is appropriate for use on affected areas (up to 20% BSA)1*
Patient portrayal.
*For short-term and non-continuous chronic treatment only.1
AD=atopic dermatitis; BSA=body surface area; TCS=topical corticosteroid.
See if your patients are eligible to save on their prescription >
*For short-term and non-continuous chronic treatment only.1
AD=atopic dermatitis; BSA=body surface area; TCS=topical corticosteroid.
Reference: 1. Opzelura. Prescribing Information. Incyte Corporation; 2021.


Looking for a proven topical treatment option: Henry, 32
“My AD feels all-consuming, but I don’t feel comfortable taking that next step.”
Patient portrayal.

His AD story
- Works as a landscape architect with exposure to extreme temperatures that exacerbate his AD (18% BSA)
- Experiences flare-ups of moderate AD
His treatment needs
- Has failed on TCIs but is hesitant toward systemics
- His physician has recommended dupilumab, but he is concerned about injectable administration
Patient portrayal.
See if your patients are eligible to save on their prescription >
AD=atopic dermatitis; BSA=body surface area; EASI=Eczema Area and Severity Index; TCI=topical calcineurin inhibitor; TCS=topical corticosteroid.


Needs a treatment that fits into a teenage lifestyle:
Alex, 13
“I'm tired of feeling like I'm different from other kids.”
Patient portrayal.

His AD story
- Loves baseball, but itching during games has frustrated him
- Has started seeing the school counselor due to concerns about the appearance of his lesions
His treatment needs
- His mother recognizes the impact mild to moderate AD is having, but is concerned about continuing to cycle on and off TCS
- Needs a nongreasy treatment he can fit into his daily routine to help control his itch and inflammation
Patient portrayal.
See if your patients are eligible to save on their prescription >
AD=atopic dermatitis; TCS=topical corticosteroid.